Effectiveness of Erythropoiesis-Stimulating Agent Therapy with Oral and Intravenous Iron Supplementation in Achieving Hemoglobin Targets in Stage 5 Chronic Kidney Disease Patients
DOI:
https://doi.org/10.35451/jfm.v9i1.3691Keywords:
Chronic kidney disease, Anemia, Erythropoiesis-stimulating agents, Oral iron, Intravenous ironAbstract
Background: Chronic kidney disease (CKD) is a major global health burden that is frequently accompanied by anemia due to erythropoietin deficiency and impaired iron metabolism, contributing to increased morbidity and reduced quality of life. Standard anemia management involves a combination of erythropoiesis-stimulating agents (ESAs) and iron supplementation administered either orally or intravenously. Differences in the route of iron administration may influence the effectiveness of hemoglobin (Hb) improvement. Objective: To evaluate the effectiveness of anemia therapy based on hemoglobin target achievement between ESA combined with oral iron supplementation and ESA combined with intravenous iron supplementation in patients with stage 5 CKD. Methods: This study employed a retrospective cohort observational analytic design using patients’ medical record data. A total of 186 patients were included in the study. Therapeutic effectiveness was assessed based on the achievement of an Hb increase of ≥1 g/dL within three months of therapy. Results: Baseline characteristics were comparable between the two groups, including sex (p = 0.797), age (p = 0.124), and severity of anemia (p = 0.145). The proportion of patients achieving the target Hb increase was significantly higher in the ESA plus intravenous iron group than in the ESA plus oral iron group (66.20% vs. 39.13%; p = 0.001). Mean Hb levels increased from 7.83 ± 1.37 g/dL to 8.35 ± 1.41 g/dL in the ESA plus oral iron group (ΔHb: 0.52 ± 1.38 g/dL) and from 8.00 ± 1.57 g/dL to 8.86 ± 1.32 g/dL in the ESA plus intravenous iron group (ΔHb: 0.86 ± 1.24 g/dL), although the difference in mean Hb change between groups was not statistically significant (p = 0.073). Conclusion: ESA therapy combined with intravenous iron supplementation was more effective in achieving the target hemoglobin level than ESA therapy combined with oral iron supplementation in patients with stage 5 CKD.
Downloads
References
[1] Mohtar NJ, Sugeng CE, Umboh OR. Penatalaksanaan Anemia pada Penyakit Ginjal Kronik. E-Clin. 2023;11(1):51–8.
[2] Badura K, Janc J, Wąsik J, Gnitecki S, Skwira S, Młynarska E, et al. Anemia of chronic kidney disease—a narrative review of its pathophysiology, diagnosis, and management. Biomedicines. 2024;12(6):1191. doi:10.3390/biomedicines12061191.
[3] Wittbrodt ET, James G, Kumar S, van Haalen H, Chen H, Sloand JA, et al. Contemporary outcomes of anemia in US patients with chronic kidney disease. Clin Kidney J. 2022;15(2):244–52. doi:10.1093/ckj/sfab195.
[4] Kim D, Lee J, Toyama T, Liyanage T, Woodward M, Matsushita K, et al. Prevalence and Treatment Patterns of Anaemia in Individuals With Chronic Kidney Disease Across Asia: A Systematic Review and Meta‐Analysis. Nephrology. 2025 Feb;30(2):e70002. doi:10.1111/nep.70002
[5] Karya KWS, Praptika NLP, Nurbudhi NYT, Kandarini Y. Perbandingan efektivitas dan keamanan antara roxadustat dan epoetin alfa sebagai terapi anemia pada pasien yang menjalani hemodialisis reguler: meta analisis. Intisari Sains Medis. 2021;12(3):768–76.
[6] Meriyani H, Sartikawati NKA, Putra IMAS. Pengaruh penggunaan antianemia terhadap kadar hemoglobin pasien gagal ginjal kronik. J Ilm Medicam [Internet]. 2019 [cited 2025 Aug 20];5(2). Available from: https://e-journal.unmas.ac.id/index.php/Medicamento/article/view/665
[7] Hain D, Bednarski D, Cahill M, Dix A, Foote B, Haras MS, et al. Iron-deficiency anemia in CKD: a narrative review for the kidney care team. Kidney Med. 2023;5(8):100677. doi:10.1016/j.xkme.2023.100677.
[8] Dian K N, Andayani TM, Endarti D. Cost Effectiveness Analysis (CEA) Strategi Terapi Anemia Pada Pasien Penyakit Ginjal Kronis [Internet]. 2022 [cited 2025 Aug 20]. Available from: https://repository.unar.ac.id/jspui/handle/123456789/6828
[9] Del Vecchio L, Minutolo R. ESA, iron therapy and new drugs: are there new perspectives in the treatment of anaemia? J Clin Med. 2021;10(4):839.
[10] Anumas S, Chatkrailert A, Tantiyavarong P. Maintenance intravenous iron in hemodialysis patients to minimize erythropoietin doses: a double-blinded, randomized controlled trial (the MAINTAIN IRON trial). Sci Rep. 2023;13(1):1287. doi:10.1038/s41598-023-28440-3.
[11] Zununi Vahed S, Ahmadian E, Hejazian SM, Esmaeili S, Farnood F. The impact of intravenous iron supplementation on hematinic parameters and erythropoietin requirements in hemodialysis patients. Adv Ther. 2021;38(8):4413-24. doi:10.1007/s12325-021-01826-3.
[12] Zahr SB, Allata Y, El Mansoury M, Chouhani BA, Kabbali N, El Bardai G, et al. Oral liposomal iron versus injectable iron sucrose for anemia treatment in non-dialysis chronic kidney disease patients: a non-inferiority study. Cureus [Internet]. 2024 [cited 2026 Apr 3];16(9). Available from: https://www.cureus.com/articles/280098-oral-liposomal-iron-versus-injectable-iron-sucrose-for-anemia-treatment-in-non-dialysis-chronic-kidney-disease-patients-a-non-inferiority-study.pdf
[13] Zhafira FZ, Cahyaningrum ED, Suandika M. Prevalensi dan Derajat Anemia pada Pasien Chronic Kidney Disease Hemodialisis di Purwokerto. Bali Med J. 2025;12(1):29–44.
[14] Neugarten J, Golestaneh L. Influence of sex on the progression of chronic kidney disease. In: Mayo Clinic Proceedings [Internet]. Elsevier; 2019 [cited 2026 Mar 12]. p. 1339–56. Available from: https://www.sciencedirect.com/science/article/pii/S0025619619300060
[15] Darmo L, Sartika SD, Abrar HK. Gambaran Karakteristik Anemia Pada Pasien Penyakit Ginjal Kronis Yang Dirawat Di RSUP Dr. Tadjuddin Chalid. Bosowa Med J. 2025;3(1):49–52.
[16] Guppy M, Thomas ET, Glasziou P, Clark J, Jones M, O’Hara DV, et al. Rate of decline in kidney function with age: a systematic review. BMJ Open. 2024;14(11):e089783.
[17] Nurafni S, Desminingrum T, Samsiah S. Hubungan Frekuensi Pemberian Erythropoietin Stimulating Agent (ESA) Dengan Peningkatan Hemoglobin Pasien Hemodialisa Di RSUD Ciawi. J Farm Sains Indones. 2023;6(1):17–24.
[18] Wahyuni S. Defisiensi Besi dan Anemia Defisiensi Besi: Updated Literature Review. Galen J Kedokt Dan Kesehat Mhs Malikussaleh. 2024;3(3):1–13.
[19] Memon S, Khan SN, Laghari SR, Hussain S, Ansari MA, Arain AA. Anemia of the Chronic Kidney Disease: A Comparision Between Oral and Intravenous Iron Therapy Combined with Erythropoietin. Med Res Arch [Internet]. 2025 [cited 2026 Apr 20];13(6). Available from: https://esmed.org/MRA/mra/article/view/6722
[20] Raju MR, Mookambika RV. Comparing The Effectiveness Of Intravenous Vs. Oral Iron Therapy In Patients With Chronic Kidney Disease-Associated Anemia. Res J Med Sci. 2024;18:130–5.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Restu Kristianto Noutema Zai, Yuandani, Emil Salim, Alfi Syahri Ginting
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
